Investors:

The global Flow Cytometry Market is estimated to reach $5 Billion in 2024, with a CAGR of 8% from 2019 - 2024. Customers for the clinical SCALPEL assay will be research and commercial CLIA laboratories. End-users of the research assays will be pharmaceutical and biotechnology companies, and the clinical SCALPEL assays will be integrated healthcare organizations.

Deepath Medical Diagnostics is seeking First Round Funding  to support clinical validation of the technology and services. Potential Investors are encouraged to contact us.

© 2017 by Deepath Medical Diagnostics, Inc.

  • b-facebook
  • Twitter Round